Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Genitourinary 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 380Carboplatin 279Specimen Handling 266Nivolumab 257Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 207Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 147atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102fludarabine 97venetoclax 96Capecitabine 94Radiosurgery 93Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × MLN2238 × 1 year × Clear all
NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡